Bethany C. Fitzmaurice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bethany C. Fitzmaurice has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Soundy
University of Birmingham
7 shared publications - Nicola R. Heneghan
School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom
7 shared publications - Asius T. A. Rayen
Department of Pain Management, Sandwell and West Birmingham NHS Trust, Birmingham B18 7QH, UK
5 shared publications - Rebecca L. Grenfell
Clinical Research Facility, Sandwell and West Birmingham NHS Trust, Birmingham B71 4HJ, UK
3 shared publications - James D. Carroll
THOR Photomedicine Ltd., Bucks, United Kingdom
2 shared publications Alifia Tameem
1 shared publication
Latest Publications
- Open Access
- 20 June 2025
- Published by MDPI AG in Clinical and Translational Neuroscience
- Vol. 9 (3) , 29
Clinical and Experiential Outcomes of Photobiomodulation Therapy as a Treatment for Fibromyalgia: A Scoping Review in Response to NICE Recommendations
(1) Background: There has been a recent growth in evidence regarding the use, value and impact of photobiomodulation therapy for individuals with fibromyalgia. However, the nature of the evidence has, to the best of the authors’ knowledge, not been presented within a scoping review. The objective of this work is to reveal the nature of the evidence, gaps in the evidence, and a map of the evidence considering photobiomodulation therapy against established policy guidelines; (2) Methods: A scoping review was undertaken considering all academic research that has examined the experiences and impact of photobiomodulation therapy on individuals with fibromyalgia; (3) Results: Our results highlight that, indeed, there is plentiful data available to address a high proportion of the concerns portrayed by the National Institute for Healthcare and Excellence. Outcome measures are wide-ranging, albeit demonstrating heterogeneity, and the results are extremely promising; (4) Conclusion: Based on the current evidence, the United Kingdom’s ‘standard of care’ for fibromyalgia needs to be ascertained, and stringent cost-effectiveness data needs to be collected and presented to governing bodies with the aim of integrating recommendations into future healthcare guidelines.
- 20 June 2025
- Published by MDPI AG in Clinical and Translational Neuroscience
- Vol. 9 (3) , 29
Open AccessClinical and Experiential Outcomes of Photobiomodulation Therapy as a Treatment for Fibromyalgia: A Scoping Review in Response to NICE Recommendations
(1) Background: There has been a recent growth in evidence regarding the use, value and impact of photobiomodulation therapy for individuals with fibromyalgia. However, the nature of the evidence has, to the best of the authors’ knowledge, not been presented within a scoping review. The objective of this work is to reveal the nature of the evidence, gaps in the evidence, and a map of the evidence considering photobiomodulation therapy against established policy guidelines; (2) Methods: A scoping review was undertaken considering all academic research that has examined the experiences and impact of photobiomodulation therapy on individuals with fibromyalgia; (3) Results: Our results highlight that, indeed, there is plentiful data available to address a high proportion of the concerns portrayed by the National Institute for Healthcare and Excellence. Outcome measures are wide-ranging, albeit demonstrating heterogeneity, and the results are extremely promising; (4) Conclusion: Based on the current evidence, the United Kingdom’s ‘standard of care’ for fibromyalgia needs to be ascertained, and stringent cost-effectiveness data needs to be collected and presented to governing bodies with the aim of integrating recommendations into future healthcare guidelines.
- Open Access
- 9 May 2025
- Published by MDPI AG in Preprints.org
Clinical and Experiential Outcomes of Photobiomodulation Therapy as a Treatment for Fibromyalgia: A Scoping Review in Response to NICE Recommendations
There is a recent growth in evidence around the use, value and impact of photobiomodulation therapy for individuals with fibromyalgia. However, the nature of the evidence, has, to the best of the authors’ knowledge not been presented within a scoping review. The objective of this work is to reveal the nature of the evidence, gaps in the evidence and map of the evidence considering photobiomodulation therapy against established policy guidelines. A scoping review was undertaken considering all academic evidence that has examined the experiences and impact of photobiomodulation therapy on individuals with fibromyalgia. Our results highlight that indeed there is plentiful data available to address a high proportion of concerns portrayed by the National Institute for Healthcare and Excellence. Outcome measures are wide ranging, albeit demonstrating heterogeneity, and results are extremely promising. Based on the current evidence base, the United Kingdom ‘standard of care’ for fibromyalgia needs to be ascertained, and stringent cost-effectiveness data needs to be collected and presented to governing bodies with the aim of integrating recommendations into future healthcare guidelines.
- 9 May 2025
- Published by MDPI AG in Preprints.org
Open AccessClinical and Experiential Outcomes of Photobiomodulation Therapy as a Treatment for Fibromyalgia: A Scoping Review in Response to NICE Recommendations
There is a recent growth in evidence around the use, value and impact of photobiomodulation therapy for individuals with fibromyalgia. However, the nature of the evidence, has, to the best of the authors’ knowledge not been presented within a scoping review. The objective of this work is to reveal the nature of the evidence, gaps in the evidence and map of the evidence considering photobiomodulation therapy against established policy guidelines. A scoping review was undertaken considering all academic evidence that has examined the experiences and impact of photobiomodulation therapy on individuals with fibromyalgia. Our results highlight that indeed there is plentiful data available to address a high proportion of concerns portrayed by the National Institute for Healthcare and Excellence. Outcome measures are wide ranging, albeit demonstrating heterogeneity, and results are extremely promising. Based on the current evidence base, the United Kingdom ‘standard of care’ for fibromyalgia needs to be ascertained, and stringent cost-effectiveness data needs to be collected and presented to governing bodies with the aim of integrating recommendations into future healthcare guidelines.
- Open Access
- 17 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 1116
Whole-Body Photobiomodulation Therapy Propels the Fibromyalgia Patient into the Recomposition Phase: A Reflexive Thematic Analysis
Background: Recent evidence has identified great promise for the novel whole-body photobiomodulation therapy (PBMT) for individuals with fibromyalgia (FM). However, currently no evidence has documented the experiences of participants. The objective of this study was to qualitatively assess treatment experience and response in a group of participants with FM undergoing a course of whole-body PBMT. Methods: An interpretive hermeneutic phenomenological study situated within the worldview of pragmatism was undertaken. A convenience sample of individuals with FM were included if they had undertaken a novel 6-week trial of PBMT. Individuals undertook semi-structured interviews exploring treatment experience and multidimensional treatment responses during Week 3 and Week 6. Results: Sixteen trial participants (47.3 ± 10.9 years) took part in this study. The analysis produced three overarching themes that were previously identified from a baseline study (namely, ‘Body Structure & Function’, ‘Activities & Participation’, and ‘Environment’) with an additional five sub-themes that highlighted the intervention experience. Subsequently, four important processes were observed and identified: increased motivation; feeling proud; improved confidence; feeling like ‘old self’. This ultimately culminated in the identification of a positive spiral, which we have termed ‘recomposition’. Conclusions: We believe our study is the first in the field of chronic pain management to utilise qualitative methodology to directly assess the acceptability and efficacy of a specific medical intervention in a clinical trial, and the first study to qualitatively assess whole-body PBMT experience. The findings are compelling and warrant further work to support the introduction of this device into the National Health Service (NHS).
- 17 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 1116
Open AccessWhole-Body Photobiomodulation Therapy Propels the Fibromyalgia Patient into the Recomposition Phase: A Reflexive Thematic Analysis
Background: Recent evidence has identified great promise for the novel whole-body photobiomodulation therapy (PBMT) for individuals with fibromyalgia (FM). However, currently no evidence has documented the experiences of participants. The objective of this study was to qualitatively assess treatment experience and response in a group of participants with FM undergoing a course of whole-body PBMT. Methods: An interpretive hermeneutic phenomenological study situated within the worldview of pragmatism was undertaken. A convenience sample of individuals with FM were included if they had undertaken a novel 6-week trial of PBMT. Individuals undertook semi-structured interviews exploring treatment experience and multidimensional treatment responses during Week 3 and Week 6. Results: Sixteen trial participants (47.3 ± 10.9 years) took part in this study. The analysis produced three overarching themes that were previously identified from a baseline study (namely, ‘Body Structure & Function’, ‘Activities & Participation’, and ‘Environment’) with an additional five sub-themes that highlighted the intervention experience. Subsequently, four important processes were observed and identified: increased motivation; feeling proud; improved confidence; feeling like ‘old self’. This ultimately culminated in the identification of a positive spiral, which we have termed ‘recomposition’. Conclusions: We believe our study is the first in the field of chronic pain management to utilise qualitative methodology to directly assess the acceptability and efficacy of a specific medical intervention in a clinical trial, and the first study to qualitatively assess whole-body PBMT experience. The findings are compelling and warrant further work to support the introduction of this device into the National Health Service (NHS).
- Open Access
- 11 January 2024
- Published by MDPI AG in Behavioral Sciences
- Vol. 14 (1) , 47
The Fibromyalgia Decomposition Phenomenon: A Reflexive Thematic Analysis
Research is needed that can provide an illustration of the different biopsychosocial and environmental experiences of people with fibromyalgia to consider how healthcare professionals can best engage with the challenges that are faced. Qualitative research is well-positioned to do this. The current study used interpretive hermeneutic phenomenology situated within a pragmatic worldview, the aim being to obtain a deeper exploration of the fibromyalgia experience prior to commencing a novel intervention. A purposive sample of individuals with fibromyalgia were selected to undertake a single interview. The interviews were analysed using a thematic analysis. The themes identified key processes of the experience. A total of 16 participants (mean age: 47.1 years) took part. Three themes and 15 sub-themes were identified, together with a process linking different experiences together. The research from this small cohort provides a clear identification of multiple components influencing the experience of fibromyalgia and the decisions around lifestyle and choices made. From this, a novel decomposition/recomposition spiral has been identified, which will benefit patients and healthcare professionals alike. An earlier diagnosis and, thus, earlier and broader treatment options can help to improve functional outcomes.
- 11 January 2024
- Published by MDPI AG in Behavioral Sciences
- Vol. 14 (1) , 47
Open AccessThe Fibromyalgia Decomposition Phenomenon: A Reflexive Thematic Analysis
Research is needed that can provide an illustration of the different biopsychosocial and environmental experiences of people with fibromyalgia to consider how healthcare professionals can best engage with the challenges that are faced. Qualitative research is well-positioned to do this. The current study used interpretive hermeneutic phenomenology situated within a pragmatic worldview, the aim being to obtain a deeper exploration of the fibromyalgia experience prior to commencing a novel intervention. A purposive sample of individuals with fibromyalgia were selected to undertake a single interview. The interviews were analysed using a thematic analysis. The themes identified key processes of the experience. A total of 16 participants (mean age: 47.1 years) took part. Three themes and 15 sub-themes were identified, together with a process linking different experiences together. The research from this small cohort provides a clear identification of multiple components influencing the experience of fibromyalgia and the decisions around lifestyle and choices made. From this, a novel decomposition/recomposition spiral has been identified, which will benefit patients and healthcare professionals alike. An earlier diagnosis and, thus, earlier and broader treatment options can help to improve functional outcomes.
- Open Access
- 29 August 2023
- Published by MDPI AG in Behavioral Sciences
- Vol. 13 (9) , 717
Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial
Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance with CONSORT (Consolidated Standards of Reporting Trials) guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and twenty-one trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT (outcomes measures in rheumatological clinical trials) domains, utilising a combination of participant-reported and performance-based outcome measures. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. The findings provided evidence to support a full-scale trial and showed promise regarding potential efficacy of this novel non-invasive treatment in an FM population.
- 29 August 2023
- Published by MDPI AG in Behavioral Sciences
- Vol. 13 (9) , 717
Open AccessWhole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial
Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance with CONSORT (Consolidated Standards of Reporting Trials) guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and twenty-one trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT (outcomes measures in rheumatological clinical trials) domains, utilising a combination of participant-reported and performance-based outcome measures. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. The findings provided evidence to support a full-scale trial and showed promise regarding potential efficacy of this novel non-invasive treatment in an FM population.
- Open Access
- 7 April 2023
- Published by Springer Nature in Research Square
Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial
Background Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. Methods A single-arm feasibility study was conducted in accordance to CONSORT (CONsolidated Standards of Reporting Trials) guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and 21 trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT (outcomes measures in rheumatological clinical trials) domains, utilising a combination of participant-reported and performance-based outcome measures. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Results Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. Conclusions Findings provide evidence to support a full-scale trial and shows promise regarding potential efficacy of this novel non-invasive treatment in an FM population. Trial Registration ClinicalTrials.gov trial; NCT05069363, 06/10/2021
- 7 April 2023
- Published by Springer Nature in Research Square
Open AccessWhole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial
Background Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. Methods A single-arm feasibility study was conducted in accordance to CONSORT (CONsolidated Standards of Reporting Trials) guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and 21 trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT (outcomes measures in rheumatological clinical trials) domains, utilising a combination of participant-reported and performance-based outcome measures. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Results Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. Conclusions Findings provide evidence to support a full-scale trial and shows promise regarding potential efficacy of this novel non-invasive treatment in an FM population. Trial Registration ClinicalTrials.gov trial; NCT05069363, 06/10/2021
- Open Access
Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial
Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance to CONSORT guidelines. A non- probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and 21 trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT domains, utilising a combination of participant-reported and performance-based outcome measures. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM- specific quality of life at 24 weeks remained improved compared with baseline scores. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Findings provide evidence to support a full-scale trial and shows promise regarding potential efficacy of this novel non-invasive treatment in an FM population.
Open AccessWhole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial
Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance to CONSORT guidelines. A non- probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and 21 trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT domains, utilising a combination of participant-reported and performance-based outcome measures. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM- specific quality of life at 24 weeks remained improved compared with baseline scores. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Findings provide evidence to support a full-scale trial and shows promise regarding potential efficacy of this novel non-invasive treatment in an FM population.
- Open Access
Whole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
Introduction Chronic pain conditions are a leading cause of disease and disability. They are associated with symptoms such as fatigue, sleep and mood disturbances. Minimal evidence is available to support effective treatments and alternatives treatment approaches are called for. Photobiomodulation therapy has been highlighted as one promising option. A whole-body therapy device (NovoTHOR) has recently been developed with a number of potential advantages for people with chronic pain. Research is needed to consider the feasibility of this device. Methods and analysis A single-centre single-armed (no placebo group) feasibility study with an embedded qualitative component will be conducted. The intervention will comprise 18 treatments over 6 weeks, with 6-month follow-up, in the whole-body photobiomodulation device. A non-probability sample of 20 adult participants with a clinician diagnosis of chronic axial pain, polyarthralgia, myofascial pain or widespread pain will be recruited (self-referral and clinician referral). Outcome measures will focus on acceptability of trial processes with a view to guiding a definitive randomised controlled trial. Analyses will use descriptive statistics for quantitative aspects. The qualitative element will be assessed by means of a participant-reported experience questionnaire postintervention and semistructured audio-recorded interviews at three stages; preintervention, midintervention and postintervention. The latter will be transcribed verbatim and a reflexive thematic analysis will be used to identify emerging themes. Exploratory outcomes (participant-reported and performance-based measures) will be analysed according to data distribution. Ethics and dissemination The study has received ethical approval from the Leicester Central Research and Ethics Committee. Findings will be disseminated via local chronic pain groups, public register update, submission for presentation at scientific meetings and open-access peer-reviewed journals, and via academic social networks. Trial registration number NCT05069363.
Open AccessWhole-body photobiomodulation therapy for chronic pain: a protocol for a feasibility trial
Introduction Chronic pain conditions are a leading cause of disease and disability. They are associated with symptoms such as fatigue, sleep and mood disturbances. Minimal evidence is available to support effective treatments and alternatives treatment approaches are called for. Photobiomodulation therapy has been highlighted as one promising option. A whole-body therapy device (NovoTHOR) has recently been developed with a number of potential advantages for people with chronic pain. Research is needed to consider the feasibility of this device. Methods and analysis A single-centre single-armed (no placebo group) feasibility study with an embedded qualitative component will be conducted. The intervention will comprise 18 treatments over 6 weeks, with 6-month follow-up, in the whole-body photobiomodulation device. A non-probability sample of 20 adult participants with a clinician diagnosis of chronic axial pain, polyarthralgia, myofascial pain or widespread pain will be recruited (self-referral and clinician referral). Outcome measures will focus on acceptability of trial processes with a view to guiding a definitive randomised controlled trial. Analyses will use descriptive statistics for quantitative aspects. The qualitative element will be assessed by means of a participant-reported experience questionnaire postintervention and semistructured audio-recorded interviews at three stages; preintervention, midintervention and postintervention. The latter will be transcribed verbatim and a reflexive thematic analysis will be used to identify emerging themes. Exploratory outcomes (participant-reported and performance-based measures) will be analysed according to data distribution. Ethics and dissemination The study has received ethical approval from the Leicester Central Research and Ethics Committee. Findings will be disseminated via local chronic pain groups, public register update, submission for presentation at scientific meetings and open-access peer-reviewed journals, and via academic social networks. Trial registration number NCT05069363.
- 1 June 2022
- Published by Oxford University Press (OUP)
- p. 229-262
Miscellaneous
This chapter is a collection of various miscellaneous drugs, which may be used in pain management as part of a multimodal, multidisciplinary approach, for their analgesic, anxiolytic, muscle relaxant, and/or adjuvant properties. The chapter includes a description of baclofen, bisphosphonates, botulinum toxin, calcitonin, cannabis, capsaicin, clonazepam, clonidine, contrast agents, hyaluronidase, ketamine, methocarbamol, methoxyflurane, nitrous oxide, orphenadrine, and vitamin D.
- 1 June 2022
- Published by Oxford University Press (OUP)
- p. 229-262
Miscellaneous
This chapter is a collection of various miscellaneous drugs, which may be used in pain management as part of a multimodal, multidisciplinary approach, for their analgesic, anxiolytic, muscle relaxant, and/or adjuvant properties. The chapter includes a description of baclofen, bisphosphonates, botulinum toxin, calcitonin, cannabis, capsaicin, clonazepam, clonidine, contrast agents, hyaluronidase, ketamine, methocarbamol, methoxyflurane, nitrous oxide, orphenadrine, and vitamin D.
- 4 February 2016
- Published by Wiley in Pediatric Anesthesia
- Vol. 26 (4) , 455-456
Failed fiberoptic intubation in a child with epidermolysis bullosa, rescued with combined use of the Glidescope®
Summary: We present the case of a 13‐year‐old male with epidermolysis bullosa having an elective syndactyly release. These patients present significant challenges to the anaesthetist; extreme care in patient handling is required. Recurrent and pronounced scarring of intra‐oral, pharyngeal and laryngeal tissues is a feature, resulting in a difficult airway. Following a failed intubation using a fibreoptic bronchoscope, we describe a combined technique by adding in the Glidescope®. This proved immediately successful. Its utilisation has been reported in adults. We wish to present our experience in the paediatric population, and this is the first report in a child with epidermiolysis bullosa.
- 4 February 2016
- Published by Wiley in Pediatric Anesthesia
- Vol. 26 (4) , 455-456
Failed fiberoptic intubation in a child with epidermolysis bullosa, rescued with combined use of the Glidescope®
Summary: We present the case of a 13‐year‐old male with epidermolysis bullosa having an elective syndactyly release. These patients present significant challenges to the anaesthetist; extreme care in patient handling is required. Recurrent and pronounced scarring of intra‐oral, pharyngeal and laryngeal tissues is a feature, resulting in a difficult airway. Following a failed intubation using a fibreoptic bronchoscope, we describe a combined technique by adding in the Glidescope®. This proved immediately successful. Its utilisation has been reported in adults. We wish to present our experience in the paediatric population, and this is the first report in a child with epidermiolysis bullosa.